Results 161 to 170 of about 2,118,431 (433)

THE VITAL STAINING OF MUSCLE BIOPSIES WITH METHYLENE BLUE [PDF]

, 1952
Christian Coërs
openalex   +1 more source

Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study.

Journal of Clinical Oncology, 2015
PURPOSE An increasing proportion of patients (> 30%) with node-positive breast cancer will obtain an axillary pathologic complete response after neoadjuvant chemotherapy (NAC).
J. Boileau, B. Poirier, M. Basik, C. Holloway, L. Gaboury, L. Sidéris, S. Meterissian, A. Arnaout, M. Brackstone, D. McCready, S. Karp, I. Trop, A. Lisbona, F. Wright, R. Younan, L. Provencher, E. Patocskai, A. Omeroglu, A. Robidoux   +18 more
semanticscholar   +1 more source

An Analysis of Early Renal Transplant Protocol Biopsies - the High Incidence of Subclinical Tubulitis [PDF]

, 2001
To investigate the possibility that we have been underestimating the true incidence of acute rejection, we began to perform protocol biopsies after kidney transplantation. This analysis looks at the one-week biopsies. Between March 1 and October 1, 1999,
Burdick, D'Ardenne, Hanas, Kjellstrand, Racusen, Randhawa, Rush, Rush, Rush, Saad, Seron, Shapiro, Shapiro, Shapiro, Shapiro, Solez, Starzl   +16 more
core   +1 more source

MET and NF2 alterations confer primary and early resistance to first‐line alectinib treatment in ALK‐positive non‐small‐cell lung cancer

Molecular Oncology, EarlyView.
Alectinib resistance in ALK+ NSCLC depends on treatment sequence and EML4‐ALK variants. Variant 1 exhibited off‐target resistance after first‐line treatment, while variant 3 and later lines favored on‐target mutations. Early resistance involved off‐target alterations, like MET and NF2, while on‐target mutations emerged with prolonged therapy.
Jie Hu, Ning Ding, Xiaobo Xu, Yedan Chen, Yong Zhang, Jingwen Liu, Jiebai Zhou, Hairong Bao, Donghui Zhang, Yijun Song, Yang Shao, Yuanlin Song   +11 more
wiley   +1 more source

Needle Biopsy of the Parietal Pleura in Malignant Disease [PDF]

, 1959
P. O. Leggat
openalex   +1 more source

Comparison of Targeted vs Systematic Prostate Biopsy in Men Who Are Biopsy Naive: The Prospective Assessment of Image Registration in the Diagnosis of Prostate Cancer (PAIREDCAP) Study.

JAMA Surgery, 2019
Importance Magnetic resonance imaging (MRI) guidance improves the accuracy of prostate biopsy for the detection of clinically significant prostate cancer, but the optimal use of such guidance is not yet clear.
Fuad F. Elkhoury, E. Felker, L. Kwan, A. Sisk, Merdie K. Delfin, S. Natarajan, L. Marks   +6 more
semanticscholar   +1 more source

Chemoresistome mapping in individual breast cancer patients unravels diversity in dynamic transcriptional adaptation

Molecular Oncology, EarlyView.
This study used longitudinal transcriptomics and gene‐pattern classification to uncover patient‐specific mechanisms of chemotherapy resistance in breast cancer. Findings reveal preexisting drug‐tolerant states in primary tumors and diverse gene rewiring patterns across patients, converging on a few dysregulated functional modules. Despite receiving the
Maya Dadiani, Gilgi Friedlander, Gili Perry, Nora Balint‐Lahat, Shlomit Gilad, Dana Morzaev‐Sulzbach, Anjana Shenoy, Noa Bossel Ben‐Moshe, Anya Pavlovsky, Rinat Bernstein‐Molho, Eytan Domany, Iris Barshack, Tamar Geiger, Bella Kaufman, Einav Nili Gal‐Yam   +14 more
wiley   +1 more source

Dynamic gene screening enabled identification of a 10-gene panel for early detection and progression assessment of gastric cancer

Computational and Structural Biotechnology Journal, 2023
Early diagnosis and progression assessment are critical for the timely detection and treatment of gastric cancer (GC) patients. Identification of diagnostic biomarkers for early detection of GC represents an unmet clinical need, and how these markers ...
Fei Long, Shuo Li, Yaqi Xu, Min Liu, Xuan Zhang, Junting Zhou, Yiyi Chen, Yuan Rong, Xiangyu Meng, Fubing Wang   +9 more
doaj  

Circulating tumor DNA as a liquid biopsy for cancer.

Clinical Chemistry, 2015
BACKGROUND Targeted therapies have markedly changed the treatment of cancer over the past 10 years. However, almost all tumors acquire resistance to systemic treatment as a result of tumor heterogeneity, clonal evolution, and selection.
E. Heitzer, Peter Ulz, J. Geigl
semanticscholar   +1 more source

Evaluation of KRAS and NRAS mutations in metastatic colorectal cancer: an 8‐year study of 10 754 patients in Turkey

Molecular Oncology, EarlyView.
This nationwide study evaluated KRAS and NRAS mutations in 10 754 Turkish patients with metastatic colorectal cancer. The results revealed a mutation frequency of 51.1%, with 46.6% having KRAS mutations, 4.5% having NRAS mutations, and 48.5% being wild‐type for both.
Gozde Kavgaci, Izzet Akiva, Yavuz Hakan Ozon, Hakan Berkil, Huseyin Karadayi, Omer Dizdar, Suayib Yalcin   +6 more
wiley   +1 more source